Andrew Jackson
Director of Finance/CFO chez CALIDI BIOTHERAPEUTICS, INC.
Fortune : 96 $ au 31/03/2024
Profil
Andrew C.
Jackson is currently the Chief Financial Officer at Calidi Biotherapeutics, Inc. He previously held the same position at Celladon Corp.
from 2014 to 2016, at AltheaDx, Inc. from 2016 to 2018, and at Ra Medical Systems, Inc. from 2018 to 2022.
From 2022 to 2023, he was the Chief Financial Officer at Eterna Therapeutics, Inc. Jackson received his undergraduate degree from the University of Minnesota in 1992 and his graduate degree from San Diego State University in 2006.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
CATHETER PRECISION, INC.
0,00% | 17/05/2023 | 197 ( 0,00% ) | 96 $ | 31/03/2024 |
ETERNA THERAPEUTICS INC.
-.--% | 26/04/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Andrew Jackson
| Sociétés | Poste | Début |
|---|---|---|
| CALIDI BIOTHERAPEUTICS, INC. | Director of Finance/CFO | 30/10/2023 |
Anciens postes connus de Andrew Jackson
| Sociétés | Poste | Fin |
|---|---|---|
| ETERNA THERAPEUTICS INC. | Director of Finance/CFO | 04/05/2023 |
| CATHETER PRECISION, INC. | Chief Executive Officer | 30/03/2020 |
| ALTHEADX INC | Director of Finance/CFO | 01/04/2018 |
Celladon Corp.
 Celladon Corp. BiotechnologyHealth Technology Celladon Corp. is a clinical-stage biotechnology company, engaging in the development of cardiovascular gene therapy. The company's therapeutic portfolio for diseases characterized by SERCA enzyme deficiency includes both gene therapies and small molecule compounds. Its most advanced product candidate MYDICAR uses gene therapy to target SERCA2a, an enzyme that is deficient in heart failure patients. Celladon was founded by Roger J. Hajjar and Kenneth R. Chien on December 21, 2000 and is headquartered in San Diego, CA. | Director of Finance/CFO | 01/03/2016 |
Formation de Andrew Jackson
| San Diego State University | Graduate Degree |
| University of Minnesota | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ETERNA THERAPEUTICS INC. | Health Technology |
| CALIDI BIOTHERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Celladon Corp.
Celladon Corp. BiotechnologyHealth Technology Celladon Corp. is a clinical-stage biotechnology company, engaging in the development of cardiovascular gene therapy. The company's therapeutic portfolio for diseases characterized by SERCA enzyme deficiency includes both gene therapies and small molecule compounds. Its most advanced product candidate MYDICAR uses gene therapy to target SERCA2a, an enzyme that is deficient in heart failure patients. Celladon was founded by Roger J. Hajjar and Kenneth R. Chien on December 21, 2000 and is headquartered in San Diego, CA. | Health Technology |
AltheaDx, Inc.
 AltheaDx, Inc. Pharmaceuticals: MajorHealth Technology AltheaDx, Inc. operates as a commercial stage molecular diagnostics company which specializes in pharmacogenetics. It focuses in depression and anxiety, clinical publications, and IDgenetix testing process. The company was founded by Francois Ferre and Magda Marquet and is headquartered in San Diego, CA. | Health Technology |
Ra Medical Systems, Inc.
 Ra Medical Systems, Inc. Medical SpecialtiesHealth Technology Ra Medical Systems, Inc. engages in the design, development and commercialization of excimer lasers for the treatment of vascular immune-mediated inflammatory diseases. Its product, the Destruction of Arteriosclerotic Blockages by laser Radiation Ablation (DABRA) laser and single-use catheter, together referred to as DABRA, is used as a tool in the treatment of peripheral artery disease which commonly occurs in the legs. The company was founded by Dean Irwin and Melissa Burstein on September 4, 2002 and is headquartered in Fort Mill, SC. | Health Technology |
